249 related articles for article (PubMed ID: 24425867)
1. Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.
Xu S; Hermanson DJ; Banerjee S; Ghebreselasie K; Clayton GM; Garavito RM; Marnett LJ
J Biol Chem; 2014 Mar; 289(10):6799-6808. PubMed ID: 24425867
[TBL] [Abstract][Full Text] [Related]
2. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.
Xu S; Rouzer CA; Marnett LJ
IUBMB Life; 2014 Dec; 66(12):803-11. PubMed ID: 25537198
[TBL] [Abstract][Full Text] [Related]
3. COX Inhibition Profile and Molecular Docking Studies of Some 2-(Trimethoxyphenyl)-Thiazoles.
Oniga SD; Pacureanu L; Stoica CI; Palage MD; Crăciun A; Rusu LR; Crisan EL; Araniciu C
Molecules; 2017 Sep; 22(9):. PubMed ID: 28891941
[TBL] [Abstract][Full Text] [Related]
4. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.
Świątek P; Strzelecka M; Urniaz R; Gębczak K; Gębarowski T; Gąsiorowski K; Malinka W
Bioorg Med Chem; 2017 Jan; 25(1):316-326. PubMed ID: 27842798
[TBL] [Abstract][Full Text] [Related]
6. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam.
Banerjee R; Chakraborty H; Sarkar M
Spectrochim Acta A Mol Biomol Spectrosc; 2003 Apr; 59(6):1213-22. PubMed ID: 12659890
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation as well as in silico studies of arylpiperazine-1,2-benzothiazine derivatives as novel anti-inflammatory agents.
Szczęśniak-Sięga BM; Wiatrak B; Czyżnikowska Ż; Janczak J; Wiglusz RJ; Maniewska J
Bioorg Chem; 2021 Jan; 106():104476. PubMed ID: 33250206
[TBL] [Abstract][Full Text] [Related]
8. Binding of Cu(II) complexes of oxicam NSAIDs to alternating AT and homopolymeric AT sequences: differential response to variation in backbone structure.
Chakraborty S; Sehanobish E; Sarkar M
J Biol Inorg Chem; 2012 Mar; 17(3):475-87. PubMed ID: 22270943
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.
Rowlinson SW; Kiefer JR; Prusakiewicz JJ; Pawlitz JL; Kozak KR; Kalgutkar AS; Stallings WC; Kurumbail RG; Marnett LJ
J Biol Chem; 2003 Nov; 278(46):45763-9. PubMed ID: 12925531
[TBL] [Abstract][Full Text] [Related]
10. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
[TBL] [Abstract][Full Text] [Related]
11. Direct binding of Cu(II)-complexes of oxicam NSAIDs with DNA backbone.
Roy S; Banerjee R; Sarkar M
J Inorg Biochem; 2006 Aug; 100(8):1320-31. PubMed ID: 16684565
[TBL] [Abstract][Full Text] [Related]
12. Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os.
Aman F; Hanif M; Kubanik M; Ashraf A; Söhnel T; Jamieson SM; Siddiqui WA; Hartinger CG
Chemistry; 2017 Apr; 23(20):4893-4902. PubMed ID: 28198061
[TBL] [Abstract][Full Text] [Related]
13. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
14. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
Lazer ES; Miao CK; Cywin CL; Sorcek R; Wong HC; Meng Z; Potocki I; Hoermann M; Snow RJ; Tschantz MA; Kelly TA; McNeil DW; Coutts SJ; Churchill L; Graham AG; David E; Grob PM; Engel W; Meier H; Trummlitz G
J Med Chem; 1997 Mar; 40(6):980-9. PubMed ID: 9083488
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
16. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
17. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam.
Obach RS; Kalgutkar AS; Ryder TF; Walker GS
Chem Res Toxicol; 2008 Sep; 21(9):1890-9. PubMed ID: 18707140
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the influence of NSAIDs with different COX-selectivity on histamine release from mast cells isolated from naïve and sensitized rats.
Grosman N
Int Immunopharmacol; 2007 Apr; 7(4):532-40. PubMed ID: 17321477
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin.
Tosco P; Lazzarato L
ChemMedChem; 2009 Jun; 4(6):939-45. PubMed ID: 19301318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
